Cargando…
Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
Lee Schwartzberg, MD, FACP, and Heather Greene, MSN, FNP, AOCNP®, reviewed optimal therapy for patients with hormone receptor–positive, HER2-negative breast cancer, as well as the management of adverse events associated with treatment.
Autores principales: | Schwartzberg, Lee, Greene, Heather |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857322/ https://www.ncbi.nlm.nih.gov/pubmed/33598325 http://dx.doi.org/10.6004/jadpro.2020.11.3.12 |
Ejemplares similares
-
Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments
por: Greene, Heather R., et al.
Publicado: (2020) -
Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
por: Schwartzberg, Lee S., et al.
Publicado: (2021) -
Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices
por: Abraham, Jame, et al.
Publicado: (2020) -
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019) -
Collaborative Management of Patients With Estrogen Receptor–Positive Breast Cancer
por: Schwartzberg, Lee S., et al.
Publicado: (2017)